Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bendamustine.

J A Balfour1, K L Goa

  • 1Adis International Limited, Auckland, New Zealand.

Drugs
|May 23, 2001
PubMed
Summary
This summary is machine-generated.

Bendamustine demonstrates significant efficacy in treating various lymphomas and multiple myeloma, often showing improved response rates and durable remissions. While generally well-tolerated, common side effects include hematological and gastrointestinal issues, with a low incidence of hair loss.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Velnacrine in Alzheimer's Disease : An Initial Appraisal of its Clinical Potential.

CNS drugs·2016
Same author

Levetiracetam.

CNS drugs·2013
Same author

Paroxetine : a review of its pharmacology and therapeutic potential in the management of panic disorder.

CNS drugs·2013
Same author

Adjuvanted influenza vaccine.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

Liposomal influenza vaccine.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

Becaplermin.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
Same journal

Linerixibat: First Approval.

Drugs·2026
See all related articles

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Bendamustine is a bifunctional alkylating agent.
  • It exhibits cytotoxic activity against ovarian and breast cancers.
  • Partial cross-resistance observed with other chemotherapy agents like cyclophosphamide and cisplatin.

Purpose of the Study:

  • To evaluate the efficacy of bendamustine in various hematological malignancies and solid tumors.
  • To compare bendamustine-based regimens with standard treatments.
  • To assess the safety and tolerability profile of bendamustine.

Main Methods:

  • Bendamustine administered as monotherapy or in combination chemotherapy protocols.
  • Clinical trials involving patients with Hodgkin's disease, non-Hodgkin's lymphoma (NHL), and multiple myeloma.
  • Comparative studies substituting bendamustine for cyclophosphamide in established regimens (COP, CMF).

Related Experiment Videos

Main Results:

  • Objective response rates of 61-97% in Hodgkin's disease and NHL.
  • Higher complete response rates (32% vs 11%) and more durable responses in multiple myeloma compared to melphalan/prednisone.
  • Prolonged remission duration in metastatic breast cancer when bendamustine replaced cyclophosphamide in the CMF protocol (15.2 vs 6.2 months).

Conclusions:

  • Bendamustine is an effective agent for treating lymphomas and multiple myeloma.
  • It offers advantages in terms of response rates and remission duration in specific cancers.
  • Adverse events are primarily hematological and gastrointestinal, with minimal alopecia.